| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| enprofylline | adenosine receptor a1 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Anemia Sickle Cell[MeSHID:D000755] Peripheral Vascular Diseases[MeSHID:D016491] Asthma[MeSHID:D001249] Cerebrovascular Insufficiency[MeSHID:D002561] Diabetic Neuropathies[MeSHID:D003929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,experimental | inhibitor |
| enprofylline | adenosine receptor a2a | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Anemia Sickle Cell[MeSHID:D000755] Peripheral Vascular Diseases[MeSHID:D016491] Asthma[MeSHID:D001249] Cerebrovascular Insufficiency[MeSHID:D002561] Diabetic Neuropathies[MeSHID:D003929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,experimental | inhibitor |
| enprofylline | adenosine receptor a2b | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Anemia Sickle Cell[MeSHID:D000755] Peripheral Vascular Diseases[MeSHID:D016491] Asthma[MeSHID:D001249] Cerebrovascular Insufficiency[MeSHID:D002561] Diabetic Neuropathies[MeSHID:D003929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,experimental | antagonist |
| enprofylline | adenosine receptor a3 | small molecule | NA | drugbank | Disease Management[MeSHID:D019468] Anemia Sickle Cell[MeSHID:D000755] Peripheral Vascular Diseases[MeSHID:D016491] Asthma[MeSHID:D001249] Cerebrovascular Insufficiency[MeSHID:D002561] Diabetic Neuropathies[MeSHID:D003929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved,experimental | inhibitor |
| enprofylline | phosphodiesterase 4a | NA | Successful target | TTD , DGIDB | Disease Management[MeSHID:D019468] Anemia Sickle Cell[MeSHID:D000755] Peripheral Vascular Diseases[MeSHID:D016491] Asthma[MeSHID:D001249] Cerebrovascular Insufficiency[MeSHID:D002561] Diabetic Neuropathies[MeSHID:D003929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
9.24 | approved | unknown |
| enprofylline | camp-specific 3',5'-cyclic phosphodiesterase 4a | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Anemia Sickle Cell[MeSHID:D000755] Peripheral Vascular Diseases[MeSHID:D016491] Asthma[MeSHID:D001249] Cerebrovascular Insufficiency[MeSHID:D002561] Diabetic Neuropathies[MeSHID:D003929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
9.24 | approved,experimental | inhibitor |
| enprofylline | camp-specific 3',5'-cyclic phosphodiesterase 4b | small molecule | NA | drugbank , DGIDB | Disease Management[MeSHID:D019468] Anemia Sickle Cell[MeSHID:D000755] Peripheral Vascular Diseases[MeSHID:D016491] Asthma[MeSHID:D001249] Cerebrovascular Insufficiency[MeSHID:D002561] Diabetic Neuropathies[MeSHID:D003929] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
5.79 | approved,experimental | inhibitor |
| click here to return to the previous page | ||||||||